Coleonol, colforsin, Forskolin, N,N-dimethyl-beta-alanine-5-(acetyloxy)-3-ethenyldodecahydro-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-1H-naphtho(2,1-b)pyran-6-yl ester HCl, NKH 477, NKH-477, NKH477
Name | Forskolin | ||
PubChem CID | 47936 | ||
Molecular Weight | 410.5g/mol | ||
Synonyms |
Coleonol, colforsin, Forskolin, N,N-dimethyl-beta-alanine-5-(acetyloxy)-3-ethenyldodecahydro-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-1H-naphtho(2,1-b)pyran-6-yl ester HCl, NKH 477, NKH-477, NKH477 |
||
Formula | C₂₂H₃₄O₇ | ||
SMILES | CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O | ||
InChI | 1S/C22H34O7/c1-8-19(5)11-14(25)22(27)20(6)13(24)9-10-18(3,4)16(20)15(26)17(28-12(2)23)21(22,7)29-19/h8,13,15-17,24,26-27H,1,9-11H2,2-7H3/t13-,15-,16-,17-,19-,20-,21+,22-/m0/s1 | ||
InChIKey | OHCQJHSOBUTRHG-KGGHGJDLSA-N | ||
CAS Number | 66575-29-9 | ||
ChEMBL ID | CHEMBL52606 | ||
ChEBI ID | CHEBI:42471 | ||
Herb ID | HBIN026686 | ||
Drug Bank ID | DB02587 | ||
KEGG ID | C09076 | ||
Toxicity | Organism | Test Type | Route(Dose) |
rat | LD50 | intraperitoneal(165 mg/kg) | |
mouse | LD50 | intraperitoneal(254 mg/kg) | |
rat | LD50 | oral(322 mg/kg) | |
Structure |
Download
2D
MOL
3D
MOL
|
Chineses Pinyin | MaoHouQiaoRuiHua | ||
Use Part | Whole herb | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Lamiales
-->Family: Lamiaceae
-->Genus: Plectranthus
-->Species: Plectranthus barbatus
|
Pair Name | Forskolin, Paclitaxel | |||
Partner Name | Paclitaxel | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
Down-regulation | Expression | CCNA1 | hsa8900 | |
Up-regulation | Expression | CDH1 | hsa999 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Up-regulation | Expression | PSMD9 | hsa5715 | |
Down-regulation | Expression | VIM | hsa7431 | |
In Vitro Model | NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 |
A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 | |
Result | Our findings encourage the design of future studies aimed at further exploring the Forskolin employment in NSCLC treatment. |
Pair Name | Forskolin, Ponatinib | |||
Partner Name | Ponatinib | |||
Disease Info | [ICD-11: 2A20.1] | Chronic myelogenous leukemia | Investigative | |
Gene Regulation | Down-regulation | Phosphorylation | CRKL | hsa1399 |
In Vitro Model | KCL-22 | Chronic myelogenous leukemia, BCR-ABL1 positive | Homo sapiens (Human) | CVCL_2091 |
K-562 | Blast phase chronic myelogenous leukemia | Homo sapiens (Human) | CVCL_0004 | |
HH [Human lymphoma] | Primary cutaneous T-cell non-Hodgkin lymphoma | Homo sapiens (Human) | CVCL_1280 | |
HEK293 | Healthy | Homo sapiens (Human) | CVCL_0045 | |
Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 | |
Result | This study provides new insight into the biological underpinnings of BCR-ABL-driven CML and potential rationale for investigating novel treatment strategies for patients with T315I CML. |
No. | Title | Href |
---|---|---|
1 | Forskolin affects proliferation, migration and Paclitaxel-mediated cytotoxicity in non-small-cell lung cancer cell lines via adenylyl cyclase/cAMP axis. Eur J Cell Biol. 2023 Jun;102(2):151292. doi: 10.1016/j.ejcb.2023.151292. | Click |
2 | Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Tumour Biol. 2016 Sep;37(9):12643-12654. doi: 10.1007/s13277-016-5179-7. | Click |